Nuformix plc (LON: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that it has been issued with an Official Decision to Grant Notice of Allowance for Japanese National Phase Patent Application No. 2020-555115 entitled “CRYSTALLINE TRANILAST SALTS AND THEIR PHARMACEUTICAL USE”.
NXP002 is the Company’s lead asset and a potential novel inhaled treatment for Idiopathic Pulmonary Fibrosis (“IPF”). The granted patent describes a proprietary new form of the drug tranilast, uniquely enabling delivery via an inhaled nebulised formulation. Nuformix owns two patent applications relating to crystalline forms of tranilast, one of which had already been granted globally. This second patent application, which as has already been granted in the US, specifically addresses the novel tranilast forms being progressed by the Company as a potential novel IPF treatment.
